Upcoming Earnings: Q2 '26
Estimated EPS
-$0.30
Estimated Rev
$0M
$DARE Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.20 up 60.00% YoY • Reported revenue of $0.15M up 499.58% YoY • Dare Bioscience expects existing cash and cash equivalents to fund operating needs, including planned DARE to PLAY commercial launch activities, into Q4 2026, though 2026 revenue is uncertain.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q2 '26 | -$0.30 | -- | -- | N/A |
Q1 '26 | -$0.31 | -$0.20 | 34.43% | BEAT |
Q4 '25 | -$0.44 | $0.03 | 106.82% | BEAT |
Q3 '25 | -$0.38 | -$0.28 | 27.09% | BEAT |
Q2 '25 | -$0.58 | -$0.45 | 22.46% | BEAT |